Compare Medpace Holdings Inc (MEDP) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Medpace Holdings Inc trades at $533.71 (market cap $15.08B), while Norwegian Cruise Line Holdings Ltd trades at $19.56 (market cap $8.95B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| MEDP | NCLH | |
|---|---|---|
Market Cap | $15.08B | $8.95B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $26.94 |
52-Week Low | $308.88 | $14.79 |
Enterprise Value | $14.55B | $23.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Norwegian Cruise Line Holdings (NCLH) trades at $19.47, showing minimal daily movement with a 0.05% gain. The stock demonstrates strong fundamental momentum with three consecutive quarterly earnings beats and improving profitability metrics. Recent technical indicators show mixed signals with a bearish overall trend but neutral oscillators. The company maintains solid revenue growth, reaching $9.83 billion in 2025, while navigating significant capital expenditures for fleet expansion.
NCLH presents a compelling value opportunity with attractive valuation ratios (P/E: 15.69, P/S: 0.94) and strong analyst support (55.55% buy ratings). However, investors face risks from high debt levels ($13.1 billion total debt) and sensitivity to macroeconomic factors affecting travel demand. The upcoming Q2 2026 earnings report on July 30 represents a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
